Avantor (NYSE:AVTR) Reaches New 12-Month Low – What’s Next?

Shares of Avantor, Inc. (NYSE:AVTR) hit a new 52-week low during mid-day trading on Saturday . The company traded as low as $19.08 and last traded at $19.15, with a volume of 14256681 shares trading hands. The stock had previously closed at $21.70.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Wells Fargo & Company decreased their target price on Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, October 28th. Raymond James decreased their price objective on Avantor from $29.00 to $26.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 21st. Barclays boosted their price objective on Avantor from $25.00 to $26.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. UBS Group restated a “neutral” rating and set a $25.00 target price (down previously from $29.00) on shares of Avantor in a research note on Friday, January 17th. Finally, Robert W. Baird dropped their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 28th. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $27.46.

Avantor Trading Down 11.8 %

The stock has a market cap of $13.03 billion, a P/E ratio of 41.63, a price-to-earnings-growth ratio of 3.97 and a beta of 1.28. The stock’s 50-day moving average is $21.76 and its two-hundred day moving average is $23.46. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06.

Avantor (NYSE:AVTR) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same quarter in the prior year, the firm posted $0.22 earnings per share. Equities research analysts anticipate that Avantor, Inc. will post 0.98 EPS for the current year.

Institutional Trading of Avantor

Large investors have recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System boosted its position in shares of Avantor by 0.3% during the 4th quarter. Louisiana State Employees Retirement System now owns 188,900 shares of the company’s stock valued at $3,980,000 after acquiring an additional 500 shares during the last quarter. Hantz Financial Services Inc. lifted its position in Avantor by 2.1% during the third quarter. Hantz Financial Services Inc. now owns 24,900 shares of the company’s stock valued at $644,000 after purchasing an additional 503 shares during the last quarter. Blue Trust Inc. grew its stake in shares of Avantor by 6.9% in the 4th quarter. Blue Trust Inc. now owns 8,069 shares of the company’s stock worth $170,000 after buying an additional 522 shares in the last quarter. Pacer Advisors Inc. grew its stake in shares of Avantor by 0.5% in the 4th quarter. Pacer Advisors Inc. now owns 99,825 shares of the company’s stock worth $2,103,000 after buying an additional 542 shares in the last quarter. Finally, Veracity Capital LLC increased its holdings in shares of Avantor by 1.0% in the 3rd quarter. Veracity Capital LLC now owns 52,359 shares of the company’s stock worth $1,355,000 after buying an additional 543 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.